HUTCHMED’s three cancer drugs remain on China’s NRDL from January 1, 2027
AI Summary- HUTCHMED said ELUNATE, ORPATHYS and SULANDA will remain included in China’s updated NRDL.
- The updated list takes effect January 1, 2027, after HUTCHMED renewed its NHSA contract.
- ELUNATE and ORPATHYS receive new or renewed indications, while SULANDA retains existing coverage.